Age, Biography and Wiki
Draft:David K. Gifford was born on 1954, is a Computer science professor. Discover Draft:David K. Gifford's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 70 years old?
Popular As |
N/A |
Occupation |
Computer science professor |
Age |
70 years old |
Zodiac Sign |
N/A |
Born |
1954 |
Birthday |
|
Birthplace |
N/A |
Nationality |
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous Computer with the age 70 years old group.
Draft:David K. Gifford Height, Weight & Measurements
At 70 years old, Draft:David K. Gifford height not available right now. We will update Draft:David K. Gifford's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
Physical Status |
Height |
Not Available |
Weight |
Not Available |
Body Measurements |
Not Available |
Eye Color |
Not Available |
Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Family |
Parents |
Not Available |
Wife |
Not Available |
Sibling |
Not Available |
Children |
Not Available |
Draft:David K. Gifford Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Draft:David K. Gifford worth at the age of 70 years old? Draft:David K. Gifford’s income source is mostly from being a successful Computer. He is from . We have estimated Draft:David K. Gifford's net worth, money, salary, income, and assets.
Net Worth in 2024 |
$1 Million - $5 Million |
Salary in 2024 |
Under Review |
Net Worth in 2023 |
Pending |
Salary in 2023 |
Under Review |
House |
Not Available |
Cars |
Not Available |
Source of Income |
Computer |
Draft:David K. Gifford Social Network
Instagram |
|
Linkedin |
|
Twitter |
|
Facebook |
|
Wikipedia |
|
Imdb |
|
Timeline
David K. Gifford (born 22 October 1954) is a computer science professor at the Massachusetts Institute of Technology (MIT) in the area of computational biology.
As a Principal Investigator in MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL), he leads research in developing interpretable computational models for drug development, immunology, genomics, and human therapeutics.
Gifford received his BS from MIT in 1976, and his PhD from Stanford University in 1981.
He joined the MIT faculty in 1982, where he is Professor of Computer Science and Engineering and Professor of Biological Engineering.
His group develops combined computational and experimental approaches to the discovery of novel biology and human therapeutics.
Some of his work involves looking at non-coding genes in the genome known as non-functional DNA.
He has collaborated on techniques for searching long stretches of the genome to identify new regions that appear to play a crucial role in gene regulation.
His group has also worked to develop drugs for specific health conditions.
His team's protocols for the direct programming of stem cells into motor neurons has shown promise as a regenerative medicine for motor neuron diseases.
More recently Gifford's group has used machine learning methods to help scientists use CRISPR, specifically with predicting DNA repair outcomes in the form of insertions or deletions.
The tool can be used to predict genetic diseases that can be cured by the direct application of CRISPR.
He has also helped create pan-variant COVID-19 vaccines that work on a wider swath of diverse populations and have been shown in mice to be able to protect against a highly pathogenic variant of COVID-19.
His company SightPath was bought by Cisco in 2002 for $800 million.
In 2011 Gifford was named a fellow of the Association for Computing Machinery for "contributions to distributed systems, e-commerce and content distribution".
Gifford has also founded multiple companies, including e-commerce site Open Market and the biotech startup Think Therapeutics.